Drug
Glepaglutide
Glepaglutide: highest development phase Phase 3, developed by Zealand Pharma. 6 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Zealand Pharma
Trials
| Drug | Phase | Indication |
|---|---|---|
| glepaglutide NCT03690206 | Phase 3 | Short Bowel Syndrome |
| Glepaglutide 10 mg NCT07228403 | Phase 3 | Short Bowel Syndrome (SBS) |
| glepaglutide NCT03905707 | Phase 3 | Short Bowel Syndrome |
| Glepaglutide NCT07197944 | Phase 3 | Short Bowel Syndrome |
| Glepaglutide NCT04881825 | Phase 3 | Short Bowel Syndrome |
| Glepaglutide NCT04178447 | Phase 1 | Renal Impairment |
Latest
No recent events.
Follow Glepaglutide on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.